ACHV · Achieve Life Sciences Inc. Common Shares
View on chartInsiders & Stakes
| Thomas Braxton King | ▼ Sell | Open Market | 315,142 Shares held | 9/4/2025 | View profile |
| Richard Alistair Stewart Executive Chairman | ▼ Sell | Open Market | 208,249 Shares held | 8/19/2026 | View profile |
| Mark K. Oki Chief Financial Officer | ▼ Sell | Open Market | 127,940 Shares held | 9/18/2025 | View profile |
| Cindy Jacobs President & CMO | ▼ Sell | Open Market | 115,585 Shares held | 9/4/2025 | View profile |
| Bencich John CHIEF FINANCIAL OFFICER | ▲ Buy | Grant | 100,636 Shares held | 8/16/2024 | View profile |
| Jaime Xinos Chief Commercial Officer | ▼ Sell | Open Market | 74,432 Shares held | 9/4/2025 | View profile |
| Jerry Wan Principal Accounting Officer | ▼ Sell | Open Market | 32,694 Shares held | 9/4/2025 | View profile |
| Clarke Anthony CSO | ▼ Sell | Tax Withholding | 3,502 Shares held | 4/28/2022 | View profile |
Transaction History
| Richard Alistair Stewart | ▼ Sell | Open Market | 20,626 | $175K | 8/19/2026 |
| Mark K. Oki | ▲ Buy | Option Exercise | 168,000 | $0 | 9/18/2025 |
| Richard Alistair Stewart | ▲ Buy | Option Exercise | 297,500 | $0 | 9/18/2025 |
| Mark K. Oki | ▼ Sell | Open Market | 50,060 | $146K | 9/18/2025 |
| Richard Alistair Stewart | ▼ Sell | Open Market | 129,501 | $378K | 9/18/2025 |
| Jerry Wan | ▲ Buy | Option Exercise | 34,100 | $0 | 9/4/2025 |
| Jerry Wan | ▼ Sell | Open Market | 14,070 | $39K | 9/4/2025 |
| Cindy Jacobs | ▲ Buy | Option Exercise | 110,000 | $0 | 9/4/2025 |
| Cindy Jacobs | ▼ Sell | Open Market | 27,629 | $77K | 9/4/2025 |
| Jaime Xinos | ▲ Buy | Option Exercise | 69,000 | $0 | 9/4/2025 |
| Jaime Xinos | ▼ Sell | Open Market | 20,854 | $58K | 9/4/2025 |
| Thomas Braxton King | ▲ Buy | Option Exercise | 455,000 | $0 | 9/4/2025 |
| Thomas Braxton King | ▼ Sell | Open Market | 139,858 | $387K | 9/4/2025 |
| Richard Alistair Stewart | ▲ Buy | Open Market | 10,000 | $29K | 3/17/2025 |
| Mark K. Oki | ▲ Buy | Open Market | 10,000 | $29K | 3/17/2025 |
| Cindy Jacobs | ▲ Buy | Grant | 2,660 | $10K | 8/16/2024 |
| Jerry Wan | ▲ Buy | Grant | 2,857 | $10K | 8/16/2024 |
| Bencich John | ▲ Buy | Grant | 5,000 | $18K | 8/16/2024 |
| Jerry Wan | ▼ Sell | Tax Withholding | 2,250 | $10K | 4/19/2024 |
| Bencich John | ▲ Buy | Option Exercise | 25,000 | $0 | 4/19/2024 |
| Richard Alistair Stewart | ▼ Sell | Tax Withholding | 10,125 | $46K | 4/19/2024 |
| Bencich John | ▼ Sell | Tax Withholding | 6,088 | $27K | 4/19/2024 |
| Jerry Wan | ▲ Buy | Option Exercise | 5,625 | $0 | 4/19/2024 |
| Cindy Jacobs | ▲ Buy | Option Exercise | 16,250 | $0 | 4/19/2024 |
| Cindy Jacobs | ▼ Sell | Tax Withholding | 3,957 | $18K | 4/19/2024 |
| Richard Alistair Stewart | ▲ Buy | Option Exercise | 22,500 | $0 | 4/19/2024 |
| Bencich John | ▲ Buy | Open Market | 10,000 | $46K | 3/4/2024 |
| Richard Alistair Stewart | ▲ Buy | Open Market | 10,000 | $46K | 3/4/2024 |
| Bencich John | ▲ Buy | Open Market | 5,000 | $28K | 5/30/2023 |
| Jerry Wan | ▲ Buy | Option Exercise | 1,250 | $0 | 4/28/2023 |
| Jerry Wan | ▼ Sell | Tax Withholding | 669 | $6K | 4/28/2023 |
| Cindy Jacobs | ▲ Buy | Option Exercise | 2,500 | $0 | 4/28/2023 |
| Cindy Jacobs | ▼ Sell | Tax Withholding | 609 | $5K | 4/28/2023 |
| Bencich John | ▲ Buy | Option Exercise | 7,500 | $0 | 4/28/2023 |
| Bencich John | ▼ Sell | Tax Withholding | 1,827 | $15K | 4/28/2023 |
| Richard Alistair Stewart | ▲ Buy | Option Exercise | 5,000 | $0 | 4/28/2023 |
| Richard Alistair Stewart | ▼ Sell | Tax Withholding | 2,250 | $19K | 4/28/2023 |
| Cindy Jacobs | ▼ Sell | Tax Withholding | 4,819 | $33K | 4/21/2023 |
| Bencich John | ▼ Sell | Tax Withholding | 7,324 | $50K | 4/21/2023 |
| Jerry Wan | ▲ Buy | Option Exercise | 5,625 | $0 | 4/21/2023 |
| Jerry Wan | ▼ Sell | Tax Withholding | 3,010 | $20K | 4/21/2023 |
| Richard Alistair Stewart | ▲ Buy | Option Exercise | 22,500 | $0 | 4/21/2023 |
| Richard Alistair Stewart | ▼ Sell | Tax Withholding | 10,125 | $69K | 4/21/2023 |
| Cindy Jacobs | ▲ Buy | Option Exercise | 16,250 | $0 | 4/21/2023 |
| Bencich John | ▲ Buy | Option Exercise | 25,000 | $0 | 4/21/2023 |
| Bencich John | ▲ Buy | Open Market | 22,000 | — | 11/18/2022 |
| Jerry Wan | ▼ Sell | Tax Withholding | 266 | $1K | 8/16/2022 |
| Jerry Wan | ▲ Buy | Grant | 2,827 | $12K | 8/16/2022 |
| Bencich John | ▲ Buy | Grant | 3,059 | $13K | 8/16/2022 |
| Cindy Jacobs | ▲ Buy | Grant | 1,817 | $8K | 8/16/2022 |
| Clarke Anthony | ▲ Buy | Option Exercise | 1,000 | $0 | 4/28/2022 |
| Clarke Anthony | ▼ Sell | Tax Withholding | 250 | $2K | 4/28/2022 |
| Jerry Wan | ▲ Buy | Option Exercise | 1,250 | $0 | 4/28/2022 |
| Jerry Wan | ▼ Sell | Tax Withholding | 669 | $5K | 4/28/2022 |
| Richard Alistair Stewart | ▲ Buy | Option Exercise | 5,000 | $0 | 4/28/2022 |
| Richard Alistair Stewart | ▼ Sell | Tax Withholding | 2,250 | $17K | 4/28/2022 |
| Cindy Jacobs | ▲ Buy | Option Exercise | 2,500 | $0 | 4/28/2022 |
| Cindy Jacobs | ▼ Sell | Tax Withholding | 609 | $5K | 4/28/2022 |
| Bencich John | ▲ Buy | Option Exercise | 7,500 | $0 | 4/28/2022 |
| Bencich John | ▼ Sell | Tax Withholding | 1,827 | $14K | 4/28/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ACHV: Downgrade noted, thesis intact; funding backs reset
Two recent SeekingAlpha articles discuss Achieve Life Sciences. One notes a rating downgrade but says the clinical thesis remains intact and the overall setup is still constructive. The other reports that the company has obtained funding to reset its manufacturing operations, indicating progress on the production side while keeping the clinical outlook unchanged.
ACHV: Downgrade noted, thesis intact; funding backs reset. Two recent SeekingAlpha articles discuss Achieve Life Sciences. One notes a rating downgrade but says the clinical thesis remains intact and the overall setup is still constructive. The other reports that the company has obtained funding to reset its manufacturing operations, indicating progress on the production side while keeping the clinical outlook unchanged.